MG-132

For research use only. Not for use in humans.

Catalog No.S2619

1062 publications

MG-132 Chemical Structure

Molecular Weight(MW): 475.62

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

Size Price Stock Quantity  
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's MG-132 had a noticeably greater effect when compared with similar products from Sigma: This is directly due to using the (S, R, S) - (-) - 2 configuration.

P21 protein can be degraded through ubiquitylation pathway. Inhibition of proteasome activities results in the accumulation of P21 protein, therefore, the more powerful the inhibiting effect, the more P21 protein is accumulated. (testing protein: P21; Cell line: Hela; treatment condition: final concentration of MG-132 is 5μM, with a 6 hour treatment time)

Selleck's MG-132 has been cited by 1062 publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.
Targets
Proteasome [9]
(Cell-free assay)
100 nM
In vitro

MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LPS-stimulated RAW264.7 cells MkLuSpVv[3Srb36gRZN{[Xl? NGj0NYszPSEQvF2= M2LFO2ROW09? NGXZfIlKdmirYnn0d{BvcXS{aXOgc5hq\GVicILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOC5zIN88US=> M1rXd|I1Pjl5NEm2
HL-60 NXGwN2c5S3m2b4TvfIlkKEG|c3H5 MVu0NEDPxE1? NVf2PFdpPDhiaB?= MnH6SG1UVw>? MoXnTWM2ODxzMDFOwG0> MmLVNlQ3QTd2OU[=
SMMC-7721 NVXqZWNbS3m2b4TvfIlkKEG|c3H5 MmrKOFAh|ryP NITlRZk1QCCq M1;6cmROW09? Mn70TWM2OD15LkGg{txO MofNNlQ3QTd2OU[=
A-549 MVHDfZRwfG:6aXOgRZN{[Xl? M2riUFQxKM7:TR?= M3f3elQ5KGh? M1XZTmROW09? NWX3VGk6UUN3MEyxNEDPxE1? NVrk[IRGOjR4OUe0PVY>
MCF-7 NUf1W4ZES3m2b4TvfIlkKEG|c3H5 M4DrZVQxKM7:TR?= NYfidG44PDhiaB?= NXvje5RqTE2VTx?= MonFTWM2OD15LkOg{txO NF3mRpQzPDZ7N{S5Oi=>
SW-480 MWLDfZRwfG:6aXOgRZN{[Xl? MYq0NEDPxE1? M1rCbFQ5KGh? Mn\QSG1UVw>? MmXJTWM2OD12IN88US=> MU[yOFY6PzR7Nh?=
NCI-H929 MXPDfZRwfG:6aXOgRZN{[Xl? NXnY[GNyOSEQvF2= Mmf2O|IhcA>? NX\RWHVqTE2VTx?= NIS2Wo9KSzVyPUCuNVch|ryP MWeyOFYzPTB6OB?=
293T MYTDfZRwfG:6aXOgRZN{[Xl? Mnq5NVAh|ryP Mm\XO|IhcA>? NV7XPIxwTE2VTx?= MYXJR|UxRDJizszN NFHVRoUzPDZ{NUC4PC=>
293T NUOzRWFXTnWwY4Tpc44hSXO|YYm= M2jzc|ExKM7:TR?= NHTrNYYzPCCq MkfESG1UVw>? M{WzdW1w\GW{YYTlcJkhcW6mdXPld{Bp\WG2LYPoc4NsKCB? M4Dxb|I1PjJ3MEi4
HeLa MX7LbY5ie2ViQYPzZZk> NF;pOm4yOCEQvF2= NXjZTopSOSCq M4\H[WROW09? NFflVo9KdmS3Y3XzJHBCWlBiY3zlZZZi\2ViYomgbY5pcWKrdHnu[{Bxem:|ZXHzc41mKGGldHn2bZR6 M3rDNlI1OzJzOEOz
MDA-MB-231 Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf2NGcyKM7:TR?= Mn3OO|IhcA>? NGrjOm9FVVOR NW[xUVNUUUN3ME2wMlE5KM7:TR?= NFLGfmwzPDF3M{KwOi=>
MCF-7 NIjVeWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCxJO69VQ>? NIO1dII4OiCq MULEUXNQ M{fZdWlEPTB;MD6xN{DPxE1? MXuyOFE2OzJyNh?=
MCF10A NYXoRWFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\Ic5BQOSEQvF2= NXnQRnExPzJiaB?= M{TVR2ROW09? M2fhNmlEPTB;MD6yPUDPxE1? MkjaNlQyPTN{ME[=
HEK-293 M2PEb2tqdmG|ZTDBd5NigQ>? M{XUVFIh[W6mIEKwJO69VQ>? M3nCOlIhcA>? MVzEUXNQ NGjNXHJKdmirYnn0d{BEcFRvTDDhZ5Rqfmm2eTD3bZRpKEmFNUCgc4YhQSCwTTC= MYOyN|U1ODd7MB?=
Calu6 NHuydoxHfW6ldHnvckBCe3OjeR?= MmLoNVAh|ryP NWnQcVE6OThiaB?= MlHNSG1UVw>? NF;3e45UcWewaX\pZ4FvfGy7IHHjZ5VufWyjdHXzJIZz[XSjeHnuJJBz\WO3coPvdi=> M4TCblI{PTB4NEi2
IFN-gamma-induced RAW264.7 MV;GeY5kfGmxbjDBd5NigQ>? M2WxT2ROW09? MV\Jcohq[mm2czDubZRzcWNib4jp[IUheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE4xPzdizszN NFrNcZYzOjJ5N{K3Oy=>
IPC227F NFzVS45EgXSxdH;4bYMhSXO|YYm= MY[xJO69VQ>? MYC0PEBp MY\EUXNQ Mmj0TWM2OD1yLkC3O{DPxE1? NULLPWJVOjF7MkS1Nlg>
Hepa-1c1c7 M3G5T2Z2dmO2aX;uJGF{e2G7 MVSyOUDPxE1? Mn;SOkBp MlGzSG1UVw>? MnHKTY5kemWjc3XzJG5z\jJicILveIVqdiCuZY\lcC=> NGnobpkzODN7MkW0OC=>
COS-7 Mm\ER5l1d3SxeHnjJGF{e2G7 NImzUnMyOCEQvF2= NHSxSZNFVVOR MmG5TWM2ODxzMDFOwG0> M3mzflE5ODh6MEm3
HuH-7 M3LQOGN6fG:2b4jpZ{BCe3OjeR?= MYqxNEDPxE1? MkDjSG1UVw>? NETYTo5KSzVyPEGwJO69VQ>? MW[xPFA5QDB7Nx?=
OCI-Ly3 NWTCRnZ[TnWwY4Tpc44hSXO|YYm= M2DCXFExKM7:TdMg MmLIOEBp M{n2SGROW09? M{P2TWlv\HWlZYOgbJVu[W5iSXvhdJBiSmGucHjhJJN1[WKrbHn6ZZRqd25id3n0bEBGSzVyIH;mJFEh|ryP MmfrNVgxOjRzMUO=
A2780 cDDP NX7BNnBYSXCxcITvd4l{KEG|c3H5 NF;oXW4zPCCq NILYNoZFVVOR MUnJcoR2[2W|IHHwc5B1d3OrczDifUBqdmirYnn0bY5oKFCWRV6g[IVoemGmYYTpc44> NIXpcY0yPzZ6NECxPC=>
LPS-stimulated RAW264.7 cells NHf3UnJHfW6ldHnvckBCe3OjeR?= MnfDSG1UVw>? MmnoTY5pcWKrdIOgUmYuc2GycHHCJGRPSSCkaX7kbY5o NV;JeYV7OTd2MEeyO|c>
PC12 NHyzXW1HfW6ldHnvckBCe3OjeR?= M3nQcVExOCEQvF5CpC=> M3LFW|I1KGh? NE\MZ2xFVVOR MWXJcohq[mm2czC2MW9JTEFvIHHu[EBJOk9{LXnu[JVk\WRiY4n0c5RwgGmlaYT5 Mly0NVcyPTh2NUS=
PC3 NGnGfWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTRVWZQOjBizszN NF3YZmU1QCCq NYL6dYw4TE2VTx?= NGnVcZVKSzVyPUCuOkDPxE1? MY[xOlY5PjV|Nx?=
LP-1 NVPqNYV7SXCxcITvd4l{KEG|c3H5 M{HkblMxOCCwTR?= Mn\ZNlQhcA>? M4XpWmROW09? NXjFPYVyUW6mdXPld{BieG:ydH;zbZMh[nliaX7jdoVie2mwZzDjcIVifmWmIGDBVnAhdGW4ZXygZY5lKHKnZIXjbY5oKE2lbD2xJJBzd3SnaX6gcIV3\Wx? MU[xOVk2QDV6OR?=
ES6 NGS0emxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nIZmlEPTB;MD6wNVMxPiEQvF2= M3T6WnNCVkeHUh?=
A101D NWjDN4J2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrnelBlUUN3ME2wMlA{Ojd7IN88US=> M3vkZXNCVkeHUh?=
OCUB-M NFL2RVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTVcnp6UUN3ME2wMlA{PzN5IN88US=> MkDmV2FPT0WU
LB2518-MEL MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTDb|JDUUN3ME2wMlA{PzZizszN NX\SNI1xW0GQR1XS
SH-4 MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMESzNUDPxE1? M33CR3NCVkeHUh?=
KNS-42 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMES0OFEh|ryP MX7TRW5ITVJ?
DSH1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nlNWlEPTB;MD6wOVI5QSEQvF2= M4\kXHNCVkeHUh?=
NTERA-S-cl-D1 M3HiZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;tcXNKSzVyPUCuNFU4PzJizszN NFLWWXRUSU6JRWK=
D-542MG MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\XOWlEPTB;MD6wOVk2PyEQvF2= NUW3WGFIW0GQR1XS
KS-1 M2LXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfySIZKSzVyPUCuNFY1PThizszN MXXTRW5ITVJ?
BL-41 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwME[5OFch|ryP NUTXSWc3W0GQR1XS
LXF-289 MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:3TWM2OD1yLkC3NFY3KM7:TR?= MUfTRW5ITVJ?
D-247MG NYfmcZpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;XTWM2OD1yLkC3NlA6KM7:TR?= M2HiXXNCVkeHUh?=
MMAC-SF NXnZTnZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjjTWM2OD1yLkC3NlY5KM7:TR?= MlL2V2FPT0WU
CP66-MEL NV;yWVlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMEe1JO69VQ>? NHO0SHpUSU6JRWK=
LB771-HNC NFK0fXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXezS2RkUUN3ME2wMlA5ODN4IN88US=> NXPFXXhiW0GQR1XS
no-10 NUT2VmNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTCNlBKSzVyPUCuNFg6ODlizszN M2DaenNCVkeHUh?=
A388 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHPTWM2OD1yLkC5NFY2KM7:TR?= M4XHcHNCVkeHUh?=
OPM-2 NVz6WWNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwMUC0O|Qh|ryP M1nGeHNCVkeHUh?=
OVCAR-4 NVraTJZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDCTWM2OD1yLkGwPVM5KM7:TR?= NUfrW2c{W0GQR1XS
HOP-62 MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHHV3FKSzVyPUCuNVA6PDlizszN MWHTRW5ITVJ?
ML-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMUG4NFYh|ryP NUPqXXhFW0GQR1XS
UACC-257 Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXzVI5lUUN3ME2wMlEyQTJ5IN88US=> M1nvb3NCVkeHUh?=
NEC8 NHvhRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TNdGlEPTB;MD6xNVk6PSEQvF2= MojHV2FPT0WU
ONS-76 NH3HXYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMUK5N|Uh|ryP M3LCOXNCVkeHUh?=
KE-37 MlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\YdmlEPTB;MD6xN|I4QCEQvF2= NVnCXmE2W0GQR1XS
HT-144 NX6zZ4hKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTNd|B[UUN3ME2wMlE{QDl3IN88US=> MXrTRW5ITVJ?
LB2241-RCC M4LTTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMUSyOFch|ryP M3q5ZnNCVkeHUh?=
TE-5 NH6wcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nUO2lEPTB;MD6xOFI4QCEQvF2= MnTpV2FPT0WU
KINGS-1 M2fjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMUS3PUDPxE1? NYTCPYR{W0GQR1XS
NCI-H69 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXZW2dKSzVyPUCuNVUyPDFizszN MoT3V2FPT0WU
CAS-1 MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwMUW0PFIh|ryP M2W5[3NCVkeHUh?=
D-263MG NEOyVpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHy[GlIUUN3ME2wMlE3ODB4IN88US=> MYTTRW5ITVJ?
A253 M3XTN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXGNWVKSzVyPUCuNVYyOjhizszN NHLzWoJUSU6JRWK=
PF-382 MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jGWWlEPTB;MD6xOlcxPiEQvF2= MWDTRW5ITVJ?
CESS MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjMZmFKSzVyPUCuNVcxPiEQvF2= Mkm3V2FPT0WU
MZ2-MEL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nvdWlEPTB;MD6xO|U2QSEQvF2= NYnFc2J[W0GQR1XS
HEL M2rMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn5eVRHUUN3ME2wMlE5PTF5IN88US=> M364WXNCVkeHUh?=
D-392MG Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrXV2tKSzVyPUCuNVkyOTVizszN MmntV2FPT0WU
SK-LMS-1 NWDI[WdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnYTWM2OD1yLkG5N|A{KM7:TR?= MkHwV2FPT0WU
GI-ME-N MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv3ZWVKSzVyPUCuNVk{ODZizszN NX7nWVJlW0GQR1XS
LB831-BLC M1vEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzMTWM2OD1yLkG5N|Qh|ryP NYTJZ5JsW0GQR1XS
DU-4475 NYHyXpVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\nXmlEPTB;MD6xPVY2QCEQvF2= NWKzcFNOW0GQR1XS
IST-SL1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkG1TWM2OD1yLkKwNFk1KM7:TR?= MX\TRW5ITVJ?
GAK NIjTSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXexSIt7UUN3ME2wMlIxPTN2IN88US=> NEDDcZZUSU6JRWK=
EW-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPTfIxKSzVyPUCuNlExPDdizszN NFqwWoRUSU6JRWK=
LAMA-84 MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{O0fGlEPTB;MD6yNVg2OSEQvF2= NXfie|JrW0GQR1XS
SK-UT-1 NGLhe|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPFemRKSzVyPUCuNlIxPDlizszN MVjTRW5ITVJ?
VA-ES-BJ NHvZPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwMkKyOVch|ryP MYLTRW5ITVJ?
ACN M3fPTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMkK2N|gh|ryP NITY[WdUSU6JRWK=
SK-PN-DW MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\6SXJKSzVyPUCuNlMyQSEQvF2= M4TkVHNCVkeHUh?=
HD-MY-Z Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ntRmlEPTB;MD6yN|MxOyEQvF2= M3;pOHNCVkeHUh?=
LB373-MEL-D NEfzWWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37wUGlEPTB;MD6yOFE6QCEQvF2= NXTVXIdZW0GQR1XS
COLO-829 Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDpdndKSzVyPUCuNlQzPTdizszN MorWV2FPT0WU
ES8 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIC4c2dKSzVyPUCuNlQ4PjNizszN NFzNeHVUSU6JRWK=
RXF393 NUnCT2hIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jwZ2lEPTB;MD6yOVAyPSEQvF2= MXPTRW5ITVJ?
TK10 MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;STWM2OD1yLkK1OFM2KM7:TR?= NULjSmhvW0GQR1XS
LOUCY NE\0TpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDsTWM2OD1yLkK1OFU3KM7:TR?= NIKxcYVUSU6JRWK=
MZ7-mel Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPWSIdKSzVyPUCuNlY{PzRizszN NIHSeWVUSU6JRWK=
CP67-MEL NIPTXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnFfHdKSzVyPUCuNlY4OyEQvF2= NYLNUWxiW0GQR1XS
C2BBe1 M3i4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMke5NFch|ryP NGP1eFhUSU6JRWK=
K052 NIHRPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMki5PUDPxE1? MWDTRW5ITVJ?
MOLT-16 NFrFbppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Px[WlEPTB;MD6yPVUzPCEQvF2= NVfkbIlNW0GQR1XS
KNS-81-FD NHXXNWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjVTWM2OD1yLkOwN|I{KM7:TR?= MVzTRW5ITVJ?
CMK MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLVN|ZKSzVyPUCuN|EyOiEQvF2= MkjwV2FPT0WU
LAN-6 M4nkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nNZWlEPTB;MD6zNVMh|ryP NYr2NFlYW0GQR1XS
KLE MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkT3TWM2OD1yLkOxN|A3KM7:TR?= MX7TRW5ITVJ?
NCCIT NXy4WFVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnJTWM2OD1yLkOxO|g{KM7:TR?= NY\ROlRPW0GQR1XS
HH NILsToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLvTWM2OD1yLkOyPFk4KM7:TR?= M2rYfnNCVkeHUh?=
TE-8 NXnSXVhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwM{SyO|kh|ryP MoPuV2FPT0WU
GDM-1 NW\mOYt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoqxTWM2OD1yLkO1NVA1KM7:TR?= MlnVV2FPT0WU
NCI-H747 NXrO[ok3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwM{exNFMh|ryP M1W1[3NCVkeHUh?=
NCI-H1092 M2q0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwM{i4OFQh|ryP NEO1W|NUSU6JRWK=
8-MG-BA Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[4d4d[UUN3ME2wMlM6QDN5IN88US=> NH\mRodUSU6JRWK=
NB17 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHm4O2xKSzVyPUCuOFI6PyEQvF2= NHv3U|hUSU6JRWK=
LC4-1 NV\4PGZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M120RmlEPTB;MD60N|YxPyEQvF2= M{fibXNCVkeHUh?=
TE-1 NETvRnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnaNItKSzVyPUCuOFUyOTlizszN NVO5Z5BFW0GQR1XS
KALS-1 M{fiemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jTeGlEPTB;MD60OlU5PCEQvF2= MluzV2FPT0WU
CCRF-CEM NGO0fmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLzZmpRUUN3ME2wMlQ4Pjd2IN88US=> MWPTRW5ITVJ?
OS-RC-2 NHrqZ2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHOTWM2OD1yLkS3PVczKM7:TR?= NV\ldmZjW0GQR1XS
A704 M3ficGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwNEi2PVIh|ryP Mn7CV2FPT0WU
BB49-HNC NX6wSGtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYro[VlZUUN3ME2wMlQ6ODl4IN88US=> MkjDV2FPT0WU
EVSA-T NYjpdmRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv3TWM2OD1yLkS5PVEyKM7:TR?= NVTXfYM1W0GQR1XS
Mo-T Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkWwTWM2OD1yLkWxO|YzKM7:TR?= NWjVR5Y{W0GQR1XS
MONO-MAC-6 NYDWVHZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\YTWM2OD1yLkWzOlEyKM7:TR?= NYXPcG9{W0GQR1XS
BB65-RCC M{DxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjIfJNKSzVyPUCuOVY5OTFizszN NEm3dHJUSU6JRWK=
NCI-H1882 Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrnTnJKSzVyPUCuOVkxOzZizszN NWLG[mNLW0GQR1XS
TE-9 NWXrXoxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\4dlNoUUN3ME2wMlYyODN|IN88US=> M1[2SHNCVkeHUh?=
NCI-H2126 NHfCfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHxVplKSzVyPUCuOlI3PjlizszN MW\TRW5ITVJ?
SF268 NIntdoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4S2TWlEPTB;MD62OVY1OSEQvF2= NW[3UodEW0GQR1XS
SW872 NFLtVVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4q0PWlEPTB;MD62OVczQSEQvF2= MljtV2FPT0WU
LS-513 NFTKPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwNk[3OVEh|ryP MmrkV2FPT0WU
NCI-H1355 MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP4TWM2OD1yLk[4OlE6KM7:TR?= MYnTRW5ITVJ?
BL-70 M2[yZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7aepJKSzVyPUCuOlk{QDhizszN NIC1TWVUSU6JRWK=
NCI-SNU-5 NGXDOXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;2eJBKSzVyPUCuOlk2PDVizszN MXvTRW5ITVJ?
SNU-C2B NGfSPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwN{C3N|kh|ryP NWrtdpMzW0GQR1XS
GB-1 NVy3UIM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3W0RmlEPTB;MD63NlEzPCEQvF2= NGfWNI5USU6JRWK=
CTB-1 M1PySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnVR|hKSzVyPUCuO|c6PTVizszN MYfTRW5ITVJ?
Becker M1n3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXNdYhKSzVyPUCuO|k3OjFizszN NWfGc|lmW0GQR1XS
KM12 NFvmOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX1SZVKSzVyPUCuPFU1PjZizszN NVrFNFJXW0GQR1XS
ES7 NY\nNlJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwOEm2OUDPxE1? NFrodo5USU6JRWK=
COLO-684 NXj2TZVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe3RZJoUUN3ME2wMlkxPjV6IN88US=> NWWwRWJuW0GQR1XS
HCC2998 MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnNSWIzUUN3ME2wMlk{QDV2IN88US=> MXLTRW5ITVJ?
TE-10 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLvTWM2OD1yLkm2OFMh|ryP MX7TRW5ITVJ?
SF126 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTZRXcyUUN3ME2wMlk5QTdzIN88US=> MojJV2FPT0WU
EKVX M3K5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH61VZJKSzVyPUGuNFM1PDJizszN M4LwWXNCVkeHUh?=
KARPAS-45 NITadFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTFwMESwNVYh|ryP M4LQbHNCVkeHUh?=
KGN NEHO[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml65TWM2OD1zLkC1NFQ2KM7:TR?= MY\TRW5ITVJ?
ES1 M1nnZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe0TWM2OD1zLkC3PVIyKM7:TR?= MlL0V2FPT0WU
L-540 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVezbnR3UUN3ME2xMlEyQDN7IN88US=> MlzBV2FPT0WU
KURAMOCHI M1rFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTFwMUKzO|Qh|ryP MWLTRW5ITVJ?
LU-65 NH\Me|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;4bZhFUUN3ME2xMlEzPzV|IN88US=> Moq1V2FPT0WU
MFH-ino M3WwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PRc2lEPTB;MT6xO|UxOSEQvF2= NH\SUVFUSU6JRWK=
NCI-H23 NWS3UXZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TUNGlEPTB;MT6yNFQyKM7:TR?= M1;PfnNCVkeHUh?=
IA-LM MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFwMkSxNVYh|ryP M3S4RXNCVkeHUh?=
PSN1 M3j5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFwMkewNVYh|ryP MnjFV2FPT0WU
NCI-H719 Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXBTWM2OD1zLkK3OFEyKM7:TR?= MXjTRW5ITVJ?
SW684 Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULSVpZtUUN3ME2xMlI5PjV7IN88US=> MVTTRW5ITVJ?
HCE-4 NFfQTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTFwM{CyNlEh|ryP NHvvZZFUSU6JRWK=
EW-16 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTFwM{GzOFch|ryP M363dnNCVkeHUh?=
NCI-H128 Mo\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTFwM{W4NVQh|ryP MlPDV2FPT0WU
HC-1 Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjUTJNOUUN3ME2xMlM5OTdizszN MXjTRW5ITVJ?
IST-MES1 M2\HTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;scpBPUUN3ME2xMlQxOjB6IN88US=> MoniV2FPT0WU
Raji NUHiV5h5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXweY1KSzVyPUGuOFE5PSEQvF2= MXLTRW5ITVJ?
DMS-114 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m0c2lEPTB;MT60OFU{QSEQvF2= NIjqNW5USU6JRWK=
GI-1 NE\vRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnmdVNbUUN3ME2xMlQ4OTNzIN88US=> MYPTRW5ITVJ?
NCI-H2081 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DjWWlEPTB;MT61OVE6PiEQvF2= M1qw[HNCVkeHUh?=
LC-1F NEDWNJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jneWlEPTB;MT61OVE6QCEQvF2= NFu2fnRUSU6JRWK=
NCI-H2227 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELTdm9KSzVyPUGuOlE2PjFizszN NYP0ZZRtW0GQR1XS
D-502MG MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HjOGlEPTB;MT62O|IyOSEQvF2= M3PTXXNCVkeHUh?=
NCI-H2141 MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvyZ2hKSzVyPUGuOlc{OTdizszN MW\TRW5ITVJ?
LS-411N MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXy5[5ZKUUN3ME2xMlY6QDB5IN88US=> NX6xZpdqW0GQR1XS
SU-DHL-1 NY\GeFZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFwN{GyPFEh|ryP MYjTRW5ITVJ?
BB30-HNC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvGdI1KSzVyPUGuO|I3QDVizszN NXTZU3BwW0GQR1XS
TE-15 NFPJOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFwOUKzO|Mh|ryP M1Ple3NCVkeHUh?=
JVM-3 NXS2dmNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nqXmlEPTB;MT65N|kxPCEQvF2= MXzTRW5ITVJ?
IST-SL2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rsTmlEPTB;Mj6wNVI2OiEQvF2= NInaPHFUSU6JRWK=
EW-18 M3PrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTRXY94UUN3ME2yMlAzOzN5IN88US=> NF[zNJNUSU6JRWK=
DJM-1 MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIni[lNKSzVyPUKuNFI2PTJizszN NW\5VW9SW0GQR1XS
no-11 NV76dZlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJwMEOxNFQh|ryP M3zvcHNCVkeHUh?=
QIMR-WIL MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7oTWM2OD1{LkG2O|YzKM7:TR?= NHXQPG5USU6JRWK=
MC-CAR NGHmZnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJwMkK5OUDPxE1? NX;QeIxbW0GQR1XS
KM-H2 NFr0WYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ridWlEPTB;Mj6yPVA1OyEQvF2= M{LNS3NCVkeHUh?=
ECC12 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLYTWM2OD1{LkO3PVQh|ryP MWjTRW5ITVJ?
HCE-T NVXlOHJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnuVGdKSzVyPUKuOFQ5QDNizszN MX;TRW5ITVJ?
MFM-223 NUjRenNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LDZmlEPTB;Mj61NFg4OSEQvF2= Ml\jV2FPT0WU
SW982 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET4VpVKSzVyPUKuOVE1QCEQvF2= Mn3UV2FPT0WU
KG-1 NXTiZ3R5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjNOWU1UUN3ME2yMlg5PzlzIN88US=> MVLTRW5ITVJ?
ES4 NGTac2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTNwME[xNVEh|ryP MXvTRW5ITVJ?
SCC-3 NXXzdYFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTNwMUC4OFgh|ryP NXvuZ2FGW0GQR1XS
RH-1 M4Cycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LN[2lEPTB;Mz6zPFc1QCEQvF2= Mn7xV2FPT0WU
NCI-H748 NVXQfJFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTNwNESyOlYh|ryP NFzDWW1USU6JRWK=
HCC2218 Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTNwNE[5N|ch|ryP NE\6NlhUSU6JRWK=
MEG-01 NIK5SIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3NTWM2OD1|LkW5Olgh|ryP M{\qPXNCVkeHUh?=
NB12 NGXDfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzSTWM2OD1|LkW5PFg5KM7:TR?= NFvBNotUSU6JRWK=
SNB75 NYr1PGtoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofVTWM2OD1|Lk[wNVA{KM7:TR?= MVnTRW5ITVJ?
KMS-12-PE MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTNwNke3NlMh|ryP NWH5OlJKW0GQR1XS
SKM-1 NIjMTWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTNwN{GzO|Yh|ryP M4f2VHNCVkeHUh?=
COLO-320-HSR NHO3Xo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTNwN{W2N|Qh|ryP NG\ibnNUSU6JRWK=
NKM-1 NYTrTmdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTNwN{ezO|gh|ryP Ml;1V2FPT0WU
TE-6 NG\VUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS2TWM2OD1|Lkm0OVYyKM7:TR?= NFfpTVdUSU6JRWK=
D-336MG NXvCVlBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonzTWM2OD12LkCxNVY3KM7:TR?= NVPtd3JPW0GQR1XS
NCI-H1650 NXjKNYpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnvTWM2OD12LkG1O|k4KM7:TR?= MmC3V2FPT0WU
ES3 MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXCPW83UUN3ME20MlMzQDJ2IN88US=> MnfBV2FPT0WU
YT NEXFempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTRwM{W0NlQh|ryP NVHX[G4zW0GQR1XS
ES5 M1vhVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTRwNECyOVUh|ryP M1vzUnNCVkeHUh?=
LB647-SCLC MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nIdWlEPTB;ND61OlMxQCEQvF2= MlfqV2FPT0WU
HAL-01 MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfkd4p[UUN3ME20MlU4ODN2IN88US=> MW\TRW5ITVJ?
LP-1 NF7pOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTRwN{KzO|Eh|ryP NF\xdVdUSU6JRWK=
BC-1 Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTVwMEC0OFch|ryP NEfMNlBUSU6JRWK=
EB-3 M3rOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe3[HlKSzVyPUWuNFMxPDFizszN NIXNfFlUSU6JRWK=
GT3TKB NX;Se21pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTVwMUe2OlIh|ryP NEO4bphUSU6JRWK=
NCI-H209 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PjWmlEPTB;NT6xPVM2OiEQvF2= MVvTRW5ITVJ?
BT-474 NXnlSYZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfueINKSzVyPUWuNlMyODJizszN NYS3TZhsW0GQR1XS
RKO MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTVwMkO0NlIh|ryP NUT2T5dzW0GQR1XS
SIMA MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfSTWM2OD13LkOwO|Y2KM7:TR?= NYPUTo0xW0GQR1XS
RL NUnXc3JjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXkW|VKSzVyPUWuN|c2PDFizszN M1freXNCVkeHUh?=
GCIY NWLscIpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVu5UlBVUUN3ME21MlQ4OjN4IN88US=> NX3DZlRpW0GQR1XS
Calu-6 M2m3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fs[GlEPTB;NT62NlIh|ryP MmexV2FPT0WU
ALL-PO NXXPWWVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTVwNkO3PVUh|ryP MXrTRW5ITVJ?
ARH-77 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHrTFNrUUN3ME21MlY4ODh5IN88US=> M2jWTXNCVkeHUh?=
A4-Fuk M{DmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjMN5VKSzVyPU[uNFgyOThizszN NUDQNW9wW0GQR1XS
NCI-H1581 NVHNSnB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWm4OItOUUN3ME22MlI{QDR7IN88US=> NI\oSnRUSU6JRWK=
HUTU-80 NXHjSZZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnmwTWM2OD14LkO2PFk4KM7:TR?= MYrTRW5ITVJ?
TGW NX\FUGZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LMfmlEPTB;Nj60OVU6OyEQvF2= NXjJfYxDW0GQR1XS
SK-N-FI Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XhS2lEPTB;Nj60OVg2PCEQvF2= NYK1ZoIyW0GQR1XS
U-266 NH;OT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrNXFVKSzVyPU[uOVE6OjZizszN MWXTRW5ITVJ?
EM-2 M2OycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7Bc|FKSzVyPU[uOlcxQTlizszN NGPNXGZUSU6JRWK=
NMC-G1 NXzaNoN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHHRnB3UUN3ME22MlcyQDl3IN88US=> NILxbGVUSU6JRWK=
KASUMI-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTZwOES3PFch|ryP NVTpRpg5W0GQR1XS
NALM-6 MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PBVGlEPTB;Nj64Olc2PCEQvF2= NFy3WWJUSU6JRWK=
OCI-AML2 M1XmWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjFO|B4UUN3ME23MlAxOzJ4IN88US=> NVP0OW1VW0GQR1XS
SHP-77 NYKyR|FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37hT2lEPTB;Nz6yNlQ{KM7:TR?= MX7TRW5ITVJ?
NOMO-1 NYLVUlBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrSUHNKSzVyPUeuNlQzPTRizszN M1vST3NCVkeHUh?=
SK-N-DZ M33Cd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4m1fmlEPTB;Nz63NVA5QSEQvF2= NUjqfI1pW0GQR1XS
LB1047-RCC M3j0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTdwN{KyN|Eh|ryP NUi4TnpkW0GQR1XS
MZ1-PC MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXBbXhlUUN3ME23Mlg3PTV6IN88US=> Ml30V2FPT0WU
NB10 NWDCNYdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYiyd2lmUUN3ME23Mlk6PTV4IN88US=> NUTafm9EW0GQR1XS
RL95-2 MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHEPYdNUUN3ME24MlExQDR{IN88US=> MVvTRW5ITVJ?
OMC-1 NHj4OFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[zTWM2OD16LkWyNVkyKM7:TR?= Mn;BV2FPT0WU
D-283MED Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRThwOUG3NVkh|ryP MYDTRW5ITVJ?
MC116 NYLU[oNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFWzVVNKSzVyPUiuPVc6PCEQvF2= M2q1bHNCVkeHUh?=
SJSA-1 NH6xWoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITqR5RKSzVyPUmuNFkxQTFizszN NVXFPGNGW0GQR1XS
JiyoyeP-2003 MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTlwMkmzNVch|ryP NEHEZ3VUSU6JRWK=
IST-MEL1 NI\2RllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYOwdVQ4UUN3ME25Mlc1OTl6IN88US=> M{n3XnNCVkeHUh?=
CTV-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[5TWM2OD1zMD6wPVc6KM7:TR?= NWj6N2N4W0GQR1XS
NH-12 M360cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS0[GdKSzVyPUGwMlI1OzNizszN NIXwRXJUSU6JRWK=
CA46 Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:wdIpKSzVyPUGwMlM3OSEQvF2= MWPTRW5ITVJ?
NCI-SNU-1 M{TzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:xVWlEPTB;MUCuOFk3QSEQvF2= MUjTRW5ITVJ?
SCLC-21H NYn3W4dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjZUoxmUUN3ME2xNE43PTl4IN88US=> MlXBV2FPT0WU
EC-GI-10 NFTwVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHabW5KSzVyPUGwMlcxOzFizszN M{f6VnNCVkeHUh?=
SR M3zZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrYTWM2OD1zMT6wNVg2KM7:TR?= MoXpV2FPT0WU
NCI-H1648 NHLHTlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlSzTWM2OD1zMT6wPVY2KM7:TR?= NE\2Zo9USU6JRWK=
TGBC1TKB M4Gwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TNOWlEPTB;MUGuOFExOiEQvF2= NUTSd|hPW0GQR1XS
EW-11 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTFzLkWxPFYh|ryP MnGxV2FPT0WU
SK-MM-2 MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPnU2JPUUN3ME2xNU45ODZzIN88US=> MnfKV2FPT0WU
NCI-H524 NHTzZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTFzLkm4NlIh|ryP Ml\DV2FPT0WU
NOS-1 M36yXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTF{LkCzOFUh|ryP NGj6T4lUSU6JRWK=
AM-38 NFf1blVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fpWGlEPTB;MUKuOVY{OyEQvF2= M1\S[XNCVkeHUh?=
A498 Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTF{LkewOlkh|ryP MXTTRW5ITVJ?
KARPAS-422 M4Lq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF70NXVKSzVyPUGyMlc1QTZizszN NIjUcHNUSU6JRWK=
LU-139 NFvDeZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIC4UYVKSzVyPUGyMlkxOjZizszN NEX5TVRUSU6JRWK=
COR-L88 NV\hSGg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXFfVFKSzVyPUGyMlk{QDJizszN NVLDdY55W0GQR1XS
K5 M2nBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;VdFNjUUN3ME2xNk46PDZ{IN88US=> MVvTRW5ITVJ?
NB13 M{jjbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\2UJpKSzVyPUGyMlk4QDNizszN NVnl[XM5W0GQR1XS
MRK-nu-1 M3;Kfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTF|LkG5OUDPxE1? NUPvU4lXW0GQR1XS
MHH-NB-11 M{XsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF|LkK5NFIh|ryP NFnnemxUSU6JRWK=
KU812 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XF[WlEPTB;MUOuOlEzPCEQvF2= NIi5ZnRUSU6JRWK=
TE-12 NFrMe3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jiOmlEPTB;MUOuOlk6PCEQvF2= NYX3PY9FW0GQR1XS
NCI-N87 M{Xnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XnVGlEPTB;MUOuO|M3KM7:TR?= M3TnOnNCVkeHUh?=
EB2 NEfJeYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK0cmlKSzVyPUGzMlg2ODVizszN NVTQVG96W0GQR1XS
DB M3zOPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn1U4RKSzVyPUGzMlk5QDVizszN NVrlRVV1W0GQR1XS
697 NHTsZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF2LkS1NVEh|ryP Mnv3V2FPT0WU
MSTO-211H NIW0W2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnJdIFKSzVyPUG0Mlc1PDhizszN NE\GboVUSU6JRWK=
JVM-2 NYTEb5BUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEG3dFJKSzVyPUG0Mlc4OzVizszN M171TXNCVkeHUh?=
COLO-824 NUXjWGVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr5cYZSUUN3ME2xOE44QTl2IN88US=> MUfTRW5ITVJ?
BC-3 NVXUc3lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTF3LkO5PEDPxE1? MmfDV2FPT0WU
BOKU NWjheHVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTF3Lkm2NFgh|ryP MVHTRW5ITVJ?
GOTO MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfJe|FKSzVyPUG2Mlk3OTdizszN MmHqV2FPT0WU
HCC2157 NGLOSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3CNllZUUN3ME2xO{41PzV3IN88US=> MWjTRW5ITVJ?
LS-1034 M4XKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTF5Lk[4NVgh|ryP NUXjfGppW0GQR1XS
CAL-148 MlvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjITWM2OD1zNz65O|k3KM7:TR?= MkHkV2FPT0WU
MOLT-4 NX3hOFV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\seJFKSzVyPUG4MlgzODhizszN M1zr[3NCVkeHUh?=
Daudi MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4n3cWlEPTB;MUiuPVI{OSEQvF2= MoX5V2FPT0WU
J-RT3-T3-5 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DKfGlEPTB;MUmuOFA3PiEQvF2= NF;aW4ZUSU6JRWK=
KMOE-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnGxTWM2OD1zOT62OFgzKM7:TR?= MYHTRW5ITVJ?
HL-60 NFPLWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3hbGRKSzVyPUKwMlE6PjVizszN MoLYV2FPT0WU
P31-FUJ M3HJUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\UPWpYUUN3ME2yNE41PzV|IN88US=> NHrP[3dUSU6JRWK=
IM-9 MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHZcYVlUUN3ME2yNE43OjJ2IN88US=> NH;hboxUSU6JRWK=
HDLM-2 NFmzcGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXm1SZoyUUN3ME2yNE45QDJzIN88US=> MUDTRW5ITVJ?
NCI-H1304 NGTNcoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITYd5BKSzVyPUKxMlA{OTFizszN M2CwcnNCVkeHUh?=
NCI-H345 M1z1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LCfWlEPTB;MkGuNFY1OyEQvF2= MorEV2FPT0WU
RPMI-6666 Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJzLkO2NFIh|ryP MmjSV2FPT0WU
GR-ST MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HVOWlEPTB;MkGuOFE4KM7:TR?= M3j5[HNCVkeHUh?=
CHP-126 NX3sbnJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfubotKSzVyPUKxMlYyQDFizszN NWPkOFZRW0GQR1XS
EHEB MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX6R|ZKSzVyPUKxMlY4OzFizszN Mki2V2FPT0WU
CPC-N MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJ2LkCyNFEh|ryP NWTqcXI2W0GQR1XS
NB1 M{PWemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLoNY5wUUN3ME2yOE43QTN7IN88US=> MkXVV2FPT0WU
LS-123 MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHOTWRKSzVyPUK0MlkxOTJizszN NHPENHhUSU6JRWK=
ST486 M1fjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Lhb2lEPTB;MkWuNVEyOyEQvF2= M4HzXnNCVkeHUh?=
NCI-H1963 M{PDeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\QbWlWUUN3ME2yOk4xPjJ|IN88US=> MXHTRW5ITVJ?
U-87-MG NGTqRldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrFSY5QUUN3ME2yOk44PjR2IN88US=> MUXTRW5ITVJ?
COR-L279 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3MTWM2OD1{Nj63PVIzKM7:TR?= NWfRTpY2W0GQR1XS
LU-165 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr0dJRKSzVyPUK4MlA5PjFizszN M4\IfnNCVkeHUh?=
COLO-800 M4m4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHLOVVNUUN3ME2yPE4zQTV4IN88US=> M1PUcHNCVkeHUh?=
ETK-1 NY\VWZczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFOyVplKSzVyPUK4MlM1PDZizszN M1f5c3NCVkeHUh?=
LNCaP-Clone-FGC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJ7LkmyPFEh|ryP NW[1VmVSW0GQR1XS
SIG-M5 NF36fWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jHSGlEPTB;M{CuO|k2OiEQvF2= MVTTRW5ITVJ?
NB6 M4LNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTNyLkm1NFMh|ryP NVu2UHhoW0GQR1XS
NCI-H2107 NF3PW2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTNzLkKzN|gh|ryP MmDPV2FPT0WU
SNU-C1 NFuy[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTNzLkOxNlYh|ryP NGX2NZhUSU6JRWK=
JAR NWLwZ4dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mni1TWM2OD1|MT6zO|k6KM7:TR?= M{\m[XNCVkeHUh?=
L-363 NIDKd2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jBXGlEPTB;M{KuNlE1PCEQvF2= NXqyfXZlW0GQR1XS
EW-24 MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfrTWM2OD1|Mj6zOFc1KM7:TR?= Mn\aV2FPT0WU
NB69 NX7IfJQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYSxTnV[UUN3ME2zN{43PDV2IN88US=> M3GxN3NCVkeHUh?=
EW-13 Mk\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\CN5lKSzVyPUOzMlg6PjlizszN MYHTRW5ITVJ?
Ramos-2G6-4C10 Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXoZYNKSzVyPUO0MlI6QTNizszN M17QdnNCVkeHUh?=
TE-11 M4\ZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PqfGlEPTB;M{SuOFgzOiEQvF2= NXjCco56W0GQR1XS
L-428 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjkfHRKSzVyPUO0Mlc2OzZizszN M1TyOnNCVkeHUh?=
KP-N-YN M3[yPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHoWG9lUUN3ME2zOE46ODV5IN88US=> MkD1V2FPT0WU
CGTH-W-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHTTWM2OD1|Nj65NFQ5KM7:TR?= MlfSV2FPT0WU
K-562 MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7iUGZKSzVyPUO3MlA5PjRizszN M{j5e3NCVkeHUh?=
NCI-H1299 MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r1UmlEPTB;M{iuNVYxOyEQvF2= M1TrXnNCVkeHUh?=
RCC10RGB NYLq[mczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoexTWM2OD1|OD6yNFg{KM7:TR?= M4XXVHNCVkeHUh?=
NCI-SNU-16 M17hS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTN6LkW2OVMh|ryP M2DPb3NCVkeHUh?=
LC-2-ad NHHKWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3P4[WlEPTB;M{muOFM{PyEQvF2= M3THe3NCVkeHUh?=
MHH-PREB-1 MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTN7LkezPFgh|ryP M4DZRXNCVkeHUh?=
NCI-H64 NX7TfItpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;WTWM2OD12MD6wPVQ5KM7:TR?= NXHEV5BEW0GQR1XS
LB996-RCC MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37Xe2lEPTB;NECuPFcyPiEQvF2= MVfTRW5ITVJ?
DEL NXHOVGJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zS[WlEPTB;NEGuOFQxPSEQvF2= M3r4OXNCVkeHUh?=
MLMA M4PyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fpfGlEPTB;NEGuO|U6PSEQvF2= NIjh[G1USU6JRWK=
SBC-1 NGCxVJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLGTWM2OD12Mj6xPFA3KM7:TR?= MlXSV2FPT0WU
MPP-89 NW[5T4hNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzIN|B3UUN3ME20Nk42QDd3IN88US=> NFn3dpNUSU6JRWK=
MV-4-11 MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLlTWM2OD12Mj65NFY4KM7:TR?= MYDTRW5ITVJ?
EoL-1- M4LsPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fVfGlEPTB;NESuNVU3QCEQvF2= NXLKbo92W0GQR1XS
CW-2 NX3mSm9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[zWotKSzVyPUS0Mlg{PDJizszN NFPXTmJUSU6JRWK=
HT M1jx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;0TWM2OD12NT63NFA4KM7:TR?= M3XtZ3NCVkeHUh?=
SW954 M3ixUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTR5LkSxNlgh|ryP MlfzV2FPT0WU
A3-KAW NIfUblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\wT2lEPTB;NEmuPFA3OSEQvF2= NFrWVmJUSU6JRWK=
TC-YIK MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[0OWVKSzVyPUWwMlA{PjNizszN NX;ZbXNUW0GQR1XS
SW962 NVnEXWY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3WzZmlEPTB;NUSuPFM2PyEQvF2= MX3TRW5ITVJ?
KP-N-RT-BM-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLhTWM2OD13Nj62OlM5KM7:TR?= M{G2UXNCVkeHUh?=
NCI-H1395 M370eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf0[lVKSzVyPUW4MlgyPzJizszN MluzV2FPT0WU
RPMI-8402 NHW4[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7hWJdSUUN3ME21PE46PTJ4IN88US=> Mn3oV2FPT0WU
SCH MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTZyLkm2N|gh|ryP M4TFfnNCVkeHUh?=
NCI-H2196 NUD6[pBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTZzLkKzNUDPxE1? MnfwV2FPT0WU
LOXIMVI NFfrNWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;GSmlEPTB;NkGuPFI3PiEQvF2= M37yfnNCVkeHUh?=
TGBC24TKB MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn6zTWM2OD14Mj6xOFkyKM7:TR?= NUi5NI5QW0GQR1XS
SK-MEL-2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7uO5B6UUN3ME22N{46QDl{IN88US=> NFvuXmFUSU6JRWK=
U-698-M M3HyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTZ6LkW2PFch|ryP MUTTRW5ITVJ?
NCI-H1522 NX:zc5Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTZ7LkCwOFch|ryP MVXTRW5ITVJ?
UACC-812 Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLwTWM2OD14OT61NlA6KM7:TR?= NIDGSJVUSU6JRWK=
MHH-CALL-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTdyLkC2JO69VQ>? M4PLPHNCVkeHUh?=
NB5 NY\JbIdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTdyLkO0Olgh|ryP NYLmdJBNW0GQR1XS
KARPAS-299 NVTRVVE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlryTWM2OD15MD60OFQ4KM7:TR?= NWXL[lZ{W0GQR1XS
NCI-H1694 M3fUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEi2Rm1KSzVyPUexMlA{OiEQvF2= NYTLU2E4W0GQR1XS
NCI-H82 Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPxOVNRUUN3ME23NU46PTB5IN88US=> M{nBO3NCVkeHUh?=
SCC-15 M1fyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLSb4VbUUN3ME23Nk4{PCEQvF2= MkT4V2FPT0WU
NCI-H1436 M4nCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLv[odKSzVyPUeyMlc1PTZizszN Mm\SV2FPT0WU
ATN-1 MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1SyRWlEPTB;N{SuOVA2KM7:TR?= NU\nUHNoW0GQR1XS
RPMI-8866 NUnxN|BqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmyTWM2OD15ND63OVA6KM7:TR?= NILpUm5USU6JRWK=
HCC1599 M1W0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHMNnJKSzVyPUe0Mlg4OzJizszN MXzTRW5ITVJ?
NCI-H1155 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfRV3JKSzVyPUe0Mlk{PjdizszN MUHTRW5ITVJ?
DOHH-2 NHf4NGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLONFF5UUN3ME23OE46PTF2IN88US=> MnrwV2FPT0WU
SK-NEP-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLrV2k3UUN3ME23OU4xPzV2IN88US=> Mk\GV2FPT0WU
HCC1187 NYnEXoJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TubWlEPTB;N{euOlEzOiEQvF2= M4CzSnNCVkeHUh?=
NCI-H322M MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfXdmVVUUN3ME23PE4{PzB7IN88US=> NF:wPHlUSU6JRWK=
NCI-H526 NXPvbI5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTd6LkW4O|ch|ryP NULxTIt3W0GQR1XS
NCI-H2171 NXPWXWNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XmNWlEPTB;N{muOFE{PiEQvF2= NF3mW2lUSU6JRWK=
COLO-668 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LydWlEPTB;OEGuOVg5PCEQvF2= MV3TRW5ITVJ?
RS4-11 MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzPc5lKSzVyPUiyMlI2ODVizszN NVTDNVNZW0GQR1XS
NCI-H716 NVzaXXBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfpTWM2OD16Mj65NFc2KM7:TR?= MlHsV2FPT0WU
LU-134-A M4LaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPwTmZQUUN3ME24N{4yOzVzIN88US=> NFO4R29USU6JRWK=
RPMI-8226 MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:yO2lEPTB;OESuNlExPyEQvF2= Mo\RV2FPT0WU
KY821 NXftN2ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvMXmdKSzVyPUmxMlY2PTFizszN MmjPV2FPT0WU
ECC4 MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LueGlEPTB;OUOuPFI3QSEQvF2= MoizV2FPT0WU
EW-3 M4LRXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTl2LkmwPFEh|ryP NX\ye4wxW0GQR1XS
NB7 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvUTWM2OD17NT63O|g3KM7:TR?= M2LacnNCVkeHUh?=
NCI-H720 M4LkVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTl6LkSwOlEh|ryP MnKwV2FPT0WU
NCI-H446 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoK2TWM2OD17OT63OVg5KM7:TR?= NFjNW5hUSU6JRWK=
NCI-H889 M4[1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rJTmlEPTB;MUC0MlI1OiEQvF2= NIf3e|JUSU6JRWK=
EW-22 NVfwOmRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13DW2lEPTB;MUC2MlE6KM7:TR?= M3\pSnNCVkeHUh?=
BV-173 Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XQb2lEPTB;MUC4MlczQCEQvF2= M3zQO3NCVkeHUh?=
WSU-NHL MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHyT3gxUUN3ME2xNFkvPjdzIN88US=> MUjTRW5ITVJ?
MN-60 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG5WotNUUN3ME2xNFkvPjlizszN Mn:wV2FPT0WU
DG-75 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rk[mlEPTB;MUGzMlM2OiEQvF2= NF23cnlUSU6JRWK=
DMS-79 NXr1dXVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\STWM2OD1zMUeuN|gzKM7:TR?= NXLicWdWW0GQR1XS
SK-MEL-1 NF;nbJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTleoxqUUN3ME2xNVgvODB7IN88US=> MnvEV2FPT0WU
DMS-153 Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF{MT63OFUh|ryP NF7yNoJUSU6JRWK=
NCI-H510A MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfSUIw2UUN3ME2xNlcvOzJizszN NX\xbI53W0GQR1XS
BE-13 M3;rVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILVPGFKSzVyPUGzOE4xPDRizszN MlKwV2FPT0WU
KP-N-YS NUfEUndlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfvTWM2OD1zM{muO|M3KM7:TR?= MWLTRW5ITVJ?
SUP-T1 NEWwVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXYTWM2OD1zNEOuO|A5KM7:TR?= M4\UdHNCVkeHUh?=
EW-12 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELjZmdKSzVyPUG0OE43QTlizszN NUfyW3U1W0GQR1XS
NB14 NULjPWt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjIPHdKSzVyPUG0O{4xQDJizszN NYLDe2lzW0GQR1XS
MDA-MB-134-VI MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjSZWpsUUN3ME2xOFgvOjZ6IN88US=> MWjTRW5ITVJ?
NCI-H1770 MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojNTWM2OD1zNU[uNlc6KM7:TR?= MYnTRW5ITVJ?
TUR MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHlTWM2OD1zNkeuPFch|ryP NYn6PYdRW0GQR1XS
NCI-H1417 NELLTVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTF6MD6zN|Eh|ryP NVrGRlJVW0GQR1XS
IMR-5 MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFG3eIRKSzVyPUG4NU42PzFizszN NFnkfIFUSU6JRWK=
NCI-H226 M3Hpbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nofGlEPTB;MUi4Mlg3PiEQvF2= MVLTRW5ITVJ?
NCI-H187 M4L2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme1TWM2OD1zOUCuNFY1KM7:TR?= NHfzWFlUSU6JRWK=
SF539 NVPMcoRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fWcmlEPTB;MUmyMlczQCEQvF2= M1HCbHNCVkeHUh?=
TALL-1 M1zqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTBTWM2OD1zOUiuN|A1KM7:TR?= MVnTRW5ITVJ?
TE-441-T M3:5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;P[2lEPTB;MUm5Mlc{QSEQvF2= M{DPe3NCVkeHUh?=
REH MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJ|Nj62NlYh|ryP MojuV2FPT0WU
MS-1 MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTJ|OT6xNlEh|ryP M{PwW3NCVkeHUh?=
THP-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJ4ND63N|gh|ryP M3nucHNCVkeHUh?=
NCI-H1838 NXnsZYU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fmUmlEPTB;MkexMlQ2PiEQvF2= MXLTRW5ITVJ?
P30-OHK MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzHUXFKSzVyPUK4N{45PDdizszN NGHIS5dUSU6JRWK=
C8166 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXyV49uUUN3ME2zOFUvOzN6IN88US=> MlPaV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western Blot
Bcr-Abl; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Ac-histone H3; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Cleaved-caspase3; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Cleaved-PARP; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

ASCL1; 

PubMed: 19765735     


MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading.

CgA; 

PubMed: 19765735     


MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading.

Nrf2; 

PubMed: 23604711     


MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells.

HO-1; 

PubMed: 23604711     


MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells.

26722260 19765735 23604711
Immunofluorescence
C2GnT-M / NMIIA; 

PubMed: 22525330     


Confocal images of bC2GnT-M and NMIIA in cells treated with DMSO (D) or MG-132 (E).

AGS3 / Vimentin; 

PubMed: 20065032     


COS-7 cells were transfected with wild-type or TPR-modified AGS3 (AGS3-TPR [M1 to E470] or AGS3-GPR [E470 to S650]) in pEGFP-N1. Thirty-six hours after transfection, cells were incubated with MG 132 (10 μM) for 12 h, and then the cells were processed for immunofluorescence microscopy. The images presented are representative of 2 to 10 separate transfections.

Bak; 

PubMed: 20557369     


Proteasome inhibitor induces Bak activation. Cells were treated with either vehicle or MG-132 at 10 µmol/L for 12 hours and were subjected to Bak immunofluorescence study using antiserum specific for the N terminus of Bak. Upon Bak activation, this epitope is no longer masked within the protein and becomes available for antibody binding upon Bak conformational change.

22525330 20065032 20557369
Growth inhibition assay
Apoptosis assay; 

PubMed: 20557369     


LX-2 cells were incubated for 24 hours in the presence of increasing concentrations of MG-132 (0, 2.5, 5, 10 µmol/L) and in the presence of the pan-caspase inhibitor QVD at 5 µmol/L for 24 hours. MG-132 and QVD were prepared in DMSO as a vehicle. All data were expressed as mean ± standard error from three individual experiments. * p < 0.01 (10 µmol/L MG-132 treated cells vs. 10 µmol/L MG-132 plus QVD treated cells)

Cell viability; 

PubMed: 26137056     


The proteasome inhibitor MG-132 significantly decreased the cell viability in EC9706 cells in a dose- and time-dependent manner.

cell proliferation ; 

PubMed: 19765735     


MG-132 significantly inhibits growth of carcinoid tumor cells in vitro. Pulmonary (NCI-H727) and GI (BON) carcinoid tumor cells were treated with MG-132 at the indicated concentrations (0 to 4µM) for up to 6 days and cell viability was measured every 2 days with the MTT assay (P<0.001). The results show that MG-132 leads to the suppression cellular proliferation in NCI-H727 (A) and BON (B) cells. (OD, optical density)

20557369 26137056 19765735
ELISA
IL-8; 

PubMed: 11160671     


ELISA of IL-8 from supernatant of eTat cells. eTat cells were blocked with Hu (2 mM) and released. MG-132 (50 μM) was added at the time of release. The supernatant was collected at 3 h postrelease and analyzed for IL-8 protein using ELISA. The result shown is representative of three independent experiments ± standard deviation. 

IL-1beta; 

PubMed: 22606244     


LPS-primed WT BMDM were incubated in control medium or medium containing 10 ng/ml ricin or 25 µg/ml cycloheximide for 4 h. MG-132 (30 µM) or Bortezimib (0.5 µM) was included as indicated. Secreted IL-1ß was measured by ELISA in triplicate wells.

11160671 22606244
In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]

Protocol

Kinase Assay:

[1]

- Collapse

Measurement of inhibitory activities of MG-132 against 20S proteasome:

The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.
Cell Research:

[3]

- Collapse
  • Cell lines: KIM-2, HC11, and ES
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 24 and 48 hours
  • Method:

    Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.


    (Only for Reference)
Animal Research:

[7]

- Collapse
  • Animal Models: Male mdx (C57BL/10ScSn DMD mdx) mice
  • Formulation: Dissolved in DMSO, and diluted in PBS
  • Dosages: ~10 μg/kg/day
  • Administration: Injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 90 mg/mL (189.22 mM)
Ethanol 25 mg/mL (52.56 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+20% propylene glycol+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage powder
in solvent
Synonyms N/A
Smiles CC(C)CC(NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1)C=O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to know whether it contains EDTA or other chelating agent in this product(S2619)?

  • Answer:

    Our S2619 MG-132 doesn't contain EDTA or other chelating agent.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID